| Synonyms | Fustin|20725-03-5|2,3-Dihydrofisetin|Dihydrofisetin|Fustin, (+)-|(+)-Fustin|3,7,3',4'-Tetrahydroxyflavanone|4382-36-9|Fustin (2R,3R)-form [MI]|UNII-4994C1X19A|(+/-)-Fustin|EINECS 243-989-6|NSC 59264|4994C1X19A|C308QR79UE|CHEMBL470267|Flavanone, 3,3',4',7- |
|---|
| Product Description | Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) is a potent amyloid β (Aβ) inhibitor. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases the expression of acetylcholine (ACh) levels, choline acetyltransferase (ChAT) activity, and ChAT gene induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) decreases in acetyl cholinesterase (AChE) activity and AChE gene expression induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases muscarinic M1 receptor gene expression and muscarinic M1 receptor binding activity. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) can be used for Alzheimer's disease research. In Vivo Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) (50-100 mg/kg; p.o.; daily, for 11days; Aβ-treated C57BL/6 mice) attenuates Aβ (1-42)-induced impairments in conditioned fear learning and passive avoidance behavior . Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) (50-100 mg/kg; p.o.; daily, for 11days; Aβ-treated C57BL/6 mice) alters Aβ (1-42)-induced changes in ACh level and AChE and ChAT activity and gene expression . Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) (50-100 mg/kg; p.o.; daily, for 11days; Aβ-treated C57BL/6 mice) increases Aβ (1-42)-induced reduction in M1 receptor mRNA and protein expression in Aβ-treated C57BL/6 mice. Fustin increases p-ERK and p-CREB expression in Aβ-treated C57BL/6 mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Aβ-treated C57BL/6 mice Dosage: 50 and 100 mg/kg Administration: Oral administration;daily, for 11days Result: Decreased freezing response in Aβ-treated C57BL/6 mice. Animal Model: Aβ-treated C57BL/6 mice Dosage: 50 and 100 mg/kg Administration: Oral administration;daily, for 11days Result: Increased the expression of Ach, ChAT gene and ChAT activity. Decreased the expression of AChE gene and AChE activity. Animal Model: Aβ-treated C57BL/6 mice Dosage: 50 and 100 mg/kg Administration: Oral administration;daily, for 11days Result: Increased gene expression of M2- , M3- ,M4-, M5-, α4β, α7-receptor, p-ERK and p-CREB. Form:Solid |
|---|
